White Matter Alterations in Spastic Paraplegia Type 5: A Multiparametric Structural MRI Study and Correlations with Biochemical Measurements

References

1. 1.↵
   1. Salinas S,
   2. Proukakis C,
   3. Crosby A, et al

   . Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol 2008;7:1127–38 doi:10.1016/S1474-4422(08)70258-8 pmid:19007737

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Schols L,
   2. Rattay TW,
   3. Martus P, et al

   . Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trial. Brain 2017;140:3112–27 doi:10.1093/brain/awx273 pmid:29126212

   CrossRefPubMed
3. 3.↵
   1. Schule R,
   2. Wiethoff S,
   3. Martus P, et al

   . Hereditary spastic paraplegia: clinicogenetic lessons from 608 patients. Ann Neurol 2016;79:646–58 doi:10.1002/ana.24611 pmid:26856398

   CrossRefPubMed
4. 4.↵
   1. Bjorkhem I,
   2. Leoni V,
   3. Meaney S

   . Genetic connections between neurological disorders and cholesterol metabolism. J Lipid Res 2010;51:2489–503 doi:10.1194/jlr.R006338 pmid:20466796

   Abstract/FREE Full Text
5. 5.↵
   1. Vance JE,
   2. Campenot RB,
   3. Vance DE

   . The synthesis and transport of lipids for axonal growth and nerve regeneration. Biochim Biophys Acta 2000;1486:84–96 doi:10.1016/s1388-1981(00)00050-0 pmid:10856715

   CrossRefPubMed
6. 6.↵
   1. Tsaousidou MK,
   2. Ouahchi K,
   3. Warner TT, et al

   . Sequence alterations within CYP7B1 implicate defective cholesterol homeostasis in motor-neuron degeneration. Am J Hum Genet 2008;82:510–15 doi:10.1016/j.ajhg.2007.10.001 pmid:18252231

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Criscuolo C,
   2. Filla A,
   3. Coppola G, et al

   . Two novel CYP7B1 mutations in Italian families with SPG5: a clinical and genetic study. J Neurol 2009;256:1252–57 doi:10.1007/s00415-009-5109-3 pmid:19363635

   CrossRefPubMed
8. 8.↵
   1. Alexander AL,
   2. Lee JE,
   3. Lazar M, et al

   . Diffusion tensor imaging of the brain. Neurotherapeutics 2007;4:316–29 doi:10.1016/j.nurt.2007.05.011 pmid:17599699

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Qiu D,
   2. Tan LH,
   3. Zhou K, et al

   . Diffusion tensor imaging of normal white matter maturation from late childhood to young adulthood: voxel-wise evaluation of mean diffusivity, fractional anisotropy, radial and axial diffusivities, and correlation with reading development. Neuroimage 2008;41:223–32 doi:10.1016/j.neuroimage.2008.02.023 pmid:18395471

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Pan MK,
    2. Huang SC,
    3. Lo YC, et al

    . Microstructural integrity of cerebral fiber tracts in hereditary spastic paraparesis with SPG11 mutation. AJNR Am J Neuroradiol 2013;34:990–96 doi:10.3174/ajnr.A3330

    Abstract/FREE Full Text
11. 11.↵
    1. Agosta F,
    2. Scarlato M,
    3. Spinelli EG, et al

    . Hereditary spastic paraplegia: beyond clinical phenotypes toward a unified pattern of central nervous system damage. Radiology 2015;276:207–18 doi:10.1148/radiol.14141715 pmid:25611737

    CrossRefPubMed
12. 12.↵
    1. Rezende TJ,
    2. de Albuquerque M,
    3. Lamas GM, et al

    . Multimodal MRI-based study in patients with SPG4 mutations. PLoS One 2015;10:e0117666 doi:10.1371/journal.pone.0117666 pmid:25658484

    CrossRefPubMed
13. 13.↵
    1. Oğuz KK,
    2. Sanverdi E,
    3. Has A, et al

    . Tract-based spatial statistics of diffusion tensor imaging in hereditary spastic paraplegia with thin corpus callosum reveals widespread white matter changes. Diagn Interv Radiol 2013;19:181–86 doi:10.5152/dir.2013.046 pmid:23302284

    CrossRefPubMed
14. 14.↵
    1. Lindig T,
    2. Bender B,
    3. Hauser TK, et al

    . Gray and white matter alterations in hereditary spastic paraplegia type SPG4 and clinical correlations. J Neurol 2015;262:1961–71 doi:10.1007/s00415-015-7791-7 pmid:26050637

    CrossRefPubMed
15. 15.↵
    1. Battiston M,
    2. Schneider T,
    3. Prados F, et al

    . Fast and reproducible in vivo T1 mapping of the human cervical spinal cord. Magn Reson Med 2018;79:2142–48 doi:10.1002/mrm.26852 pmid:28736946

    CrossRefPubMed
16. 16.↵
    1. Khalil M,
    2. Teunissen CE,
    3. Otto M, et al

    . Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018;14:577–89 doi:10.1038/s41582-018-0058-z pmid:30171200

    CrossRefPubMed
17. 17.↵
    1. Lillico R,
    2. Zhou T,
    3. Khorshid Ahmad T, et al

    . Increased post-translational lysine acetylation of myelin basic protein is associated with peak neurological disability in a mouse experimental autoimmune encephalomyelitis model of multiple sclerosis. J Proteome Res 2018;17:55–62 doi:10.1021/acs.jproteome.7b00270 pmid:29111742

    CrossRefPubMed
18. 18.↵
    1. Schule R,
    2. Holland-Letz T,
    3. Klimpe S, et al

    . The Spastic Paraplegia Rating Scale (SPRS): a reliable and valid measure of disease severity. Neurology 2006;67:430–34 doi:10.1212/01.wnl.0000228242.53336.90 pmid:16894103

    Abstract/FREE Full Text
19. 19.↵
    1. De Leener B,
    2. Levy S,
    3. Dupont SM, et al

    . SCT: Spinal Cord Toolbox, an open-source software for processing spinal cord MRI data. Neuroimage 2017;145:24–43 doi:10.1016/j.neuroimage.2016.10.009 pmid:27720818

    CrossRefPubMed
20. 20.↵
    1. Harding AE

    . Classification of the hereditary ataxias and paraplegias. Lancet 1983;1:1151–55 doi:10.1016/S0140-6736(83)92879-9 pmid:6133167

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Biancheri R,
    2. Ciccolella M,
    3. Rossi A, et al

    . White matter lesions in spastic paraplegia with mutations in SPG5/CYP7B1. Neuromuscul Disord 2009;19:62–65 doi:10.1016/j.nmd.2008.10.009 pmid:19187859

    CrossRefPubMed
22. 22.↵
    1. Chou CT,
    2. Soong BW,
    3. Lin KP, et al

    . Clinical characteristics of Taiwanese patients with hereditary spastic paraplegia type 5. Ann Clin Transl Neurol 2020;7:486–96 doi:10.1002/acn3.51019 pmid:32202070

    CrossRefPubMed
23. 23.↵
    1. Dong EL,
    2. Wang C,
    3. Wu S, et al

    . Clinical spectrum and genetic landscape for hereditary spastic paraplegias in China. Mol Neurodegener 2018;13:36 doi:10.1186/s13024-018-0269-1 pmid:29980238

    CrossRefPubMed
24. 24.↵
    1. Duning T,
    2. Warnecke T,
    3. Schirmacher A, et al

    . Specific pattern of early white-matter changes in pure hereditary spastic paraplegia. Mov Disord 2010;25:1986–92 doi:10.1002/mds.23211 pmid:20669295

    CrossRefPubMed
25. 25.↵
    1. Mignarri A,
    2. Malandrini A,
    3. Del Puppo M, et al

    . Treatment of SPG5 with cholesterol-lowering drugs. J Neurol 2015;262:2783–85 doi:10.1007/s00415-015-7971-5 pmid:26566916

    CrossRefPubMed
26. 26.↵
    1. Noguerol TM,
    2. Barousse R,
    3. Amrhein TJ, et al

    . Optimizing diffusion-tensor imaging acquisition for spinal cord assessment: physical basis and technical adjustments. Radiographics 2020;40:403–27 doi:10.1148/rg.2020190058 pmid:32125961

    CrossRefPubMed
27. 27.↵
    1. Roos P,
    2. Svenstrup K,
    3. Danielsen ER, et al

    . CYP7B1: novel mutations and magnetic resonance spectroscopy abnormalities in hereditary spastic paraplegia type 5A. Acta Neurol Scand 2014;129:330–34 doi:10.1111/ane.12188 pmid:24117163

    CrossRefPubMed
28. 28.↵
    1. Hofer S,
    2. Wang X,
    3. Roeloffs V, et al

    . Single-shot T1 mapping of the corpus callosum: a rapid characterization of fiber bundle anatomy. Front Neuroanat 2015;9:57 doi:10.3389/fnana.2015.00057 pmid:26029059

    CrossRefPubMed
29. 29.↵
    1. Takano R,
    2. Misu T,
    3. Takahashi T, et al

    . Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010;75:208–16 doi:10.1212/WNL.0b013e3181e2414b pmid:20644148

    Abstract/FREE Full Text
30. 30.↵
    1. Martin-Aguilar L,
    2. Camps-Renom P,
    3. Lleixa C, et al

    . Serum neurofilament light chain predicts long-term prognosis in Guillain-Barre syndrome patients. J Neurol Neurosurg Psychiatry 2021;92:70–77 doi:10.1136/jnnp-2020-323899 pmid:33154183

    Abstract/FREE Full Text
31. 31.↵
    1. Sejbaek T,
    2. Nielsen HH,
    3. Penner N, et al

    . Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients. J Neurol Neurosurg Psychiatry 2019;90:jnnp-2019-321321–30 doi:10.1136/jnnp-2019-321321 pmid:31611264

    Abstract/FREE Full Text
32. 32.↵
    1. Aghakhanyan G,
    2. Martinuzzi A,
    3. Frijia F, et al

    . Brain white matter involvement in hereditary spastic paraplegias: analysis with multiple diffusion tensor indices. AJNR Am J Neuroradiol 2014;35:1533–38 doi:10.3174/ajnr.A3897 pmid:24788132

    Abstract/FREE Full Text
33. 33.↵
    1. Servelhere KR,
    2. Casseb RF,
    3. de Lima FD, et al

    . Spinal cord gray and white matter damage in different hereditary spastic paraplegia subtypes. AJNR Am J Neuroradiol 2021;42:610–15 doi:10.3174/ajnr.A7017 pmid:33478946

    Abstract/FREE Full Text
34. 34.↵
    1. Castellano A,
    2. Papinutto N,
    3. Cadioli M, et al

    . Quantitative MRI of the spinal cord and brain in adrenomyeloneuropathy: in vivo assessment of structural changes. Brain 2016;139:1735–46 doi:10.1093/brain/aww068 pmid:27068048

    CrossRefPubMed
35. 35.↵
    1. Andica C,
    2. Kamagata K,
    3. Hatano T, et al

    . MR biomarkers of degenerative brain disorders derived from diffusion imaging. J Magn Reson Imaging 2020;52:1620–36 doi:10.1002/jmri.27019 pmid:31837086

    CrossRefPubMed